
Amy E. Juedes
Examiner (ID: 2036, Phone: (571)272-4471 , Office: P/1644 )
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1644 |
| Total Applications | 1271 |
| Issued Applications | 443 |
| Pending Applications | 154 |
| Abandoned Applications | 705 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18176953
[patent_doc_number] => 20230037682
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => BINDING MOLECULES AGAINST CD3 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/311315
[patent_app_country] => US
[patent_app_date] => 2019-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 136508
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311315
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/311315 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | Dec 3, 2019 | Pending |
Array
(
[id] => 15895239
[patent_doc_number] => 20200147138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => TREATMENT METHOD FOR KIDNEY TRANSPLANT REJECTION
[patent_app_type] => utility
[patent_app_number] => 16/680659
[patent_app_country] => US
[patent_app_date] => 2019-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4523
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680659
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/680659 | TREATMENT METHOD FOR KIDNEY TRANSPLANT REJECTION | Nov 11, 2019 | Abandoned |
Array
(
[id] => 15618897
[patent_doc_number] => 20200079853
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-12
[patent_title] => T REGULATORY CELLS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/680405
[patent_app_country] => US
[patent_app_date] => 2019-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12149
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680405
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/680405 | T REGULATORY CELLS AND USES THEREOF | Nov 10, 2019 | Abandoned |
Array
(
[id] => 15621225
[patent_doc_number] => 20200081017
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-12
[patent_title] => T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/675398
[patent_app_country] => US
[patent_app_date] => 2019-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 87635
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675398
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/675398 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | Nov 5, 2019 | Abandoned |
Array
(
[id] => 15524837
[patent_doc_number] => 20200054724
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 IN CHILDREN, APPLICATION OF THE CELL SORTER AND THE METHOD OF MULTIPLYING TREG CELLS TO PRODUCE THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1
[patent_app_type] => utility
[patent_app_number] => 16/661038
[patent_app_country] => US
[patent_app_date] => 2019-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2308
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16661038
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/661038 | THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 IN CHILDREN, APPLICATION OF THE CELL SORTER AND THE METHOD OF MULTIPLYING TREG CELLS TO PRODUCE THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 | Oct 22, 2019 | Abandoned |
Array
(
[id] => 18153117
[patent_doc_number] => 11566078
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-31
[patent_title] => PDL1-binding proteins
[patent_app_type] => utility
[patent_app_number] => 16/601825
[patent_app_country] => US
[patent_app_date] => 2019-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 50
[patent_no_of_words] => 22748
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16601825
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/601825 | PDL1-binding proteins | Oct 14, 2019 | Issued |
Array
(
[id] => 15457373
[patent_doc_number] => 20200041511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => EFFECTOR TYPE REGULATORY T CELL DETECTING METHOD, EFFECTOR TYPE REGULATORY T CELL ANALYZING DEVICE, EFFECTOR TYPE REGULATORY T CELL ANALYZING SYSTEM, AND NON-TRANSITORY STORAGE MEDIUM
[patent_app_type] => utility
[patent_app_number] => 16/598465
[patent_app_country] => US
[patent_app_date] => 2019-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15102
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16598465
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/598465 | EFFECTOR TYPE REGULATORY T CELL DETECTING METHOD, EFFECTOR TYPE REGULATORY T CELL ANALYZING DEVICE, EFFECTOR TYPE REGULATORY T CELL ANALYZING SYSTEM, AND NON-TRANSITORY STORAGE MEDIUM | Oct 9, 2019 | Abandoned |
Array
(
[id] => 17292551
[patent_doc_number] => 20210388390
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => INTRACELLULAR DELIVERY OF BIOMOLECULES TO ENHANCE ANTIGEN PRESENTING CELL FUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/282709
[patent_app_country] => US
[patent_app_date] => 2019-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 86194
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -110
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282709
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/282709 | INTRACELLULAR DELIVERY OF BIOMOLECULES TO ENHANCE ANTIGEN PRESENTING CELL FUNCTION | Oct 2, 2019 | Pending |
Array
(
[id] => 17068592
[patent_doc_number] => 20210270807
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => MOT CELLS AS A THERAPEUTIC SCREENING TOOL FOR REGULATORY T-CELL ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/256592
[patent_app_country] => US
[patent_app_date] => 2019-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17256592
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/256592 | MoT cells as a therapeutic screening tool for regulatory t-cell activity | Sep 24, 2019 | Issued |
Array
(
[id] => 17243502
[patent_doc_number] => 20210363245
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 17/276959
[patent_app_country] => US
[patent_app_date] => 2019-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25417
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276959
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/276959 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES | Sep 16, 2019 | Pending |
Array
(
[id] => 17742621
[patent_doc_number] => 11390678
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-19
[patent_title] => Compositions and methods for the treatment of immune related diseases
[patent_app_type] => utility
[patent_app_number] => 16/537280
[patent_app_country] => US
[patent_app_date] => 2019-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 87
[patent_no_of_words] => 51101
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16537280
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/537280 | Compositions and methods for the treatment of immune related diseases | Aug 8, 2019 | Issued |
Array
(
[id] => 15145117
[patent_doc_number] => 20190351036
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/530104
[patent_app_country] => US
[patent_app_date] => 2019-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530104
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/530104 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF | Aug 1, 2019 | Abandoned |
Array
(
[id] => 15432395
[patent_doc_number] => 20200030380
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => STIMULATION OF THERAPEUTIC ANGIOGENESIS BY T REGULATORY CELLS
[patent_app_type] => utility
[patent_app_number] => 16/502433
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11295
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502433
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/502433 | STIMULATION OF THERAPEUTIC ANGIOGENESIS BY T REGULATORY CELLS | Jul 2, 2019 | Abandoned |
Array
(
[id] => 19977200
[patent_doc_number] => 12344661
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination
[patent_app_type] => utility
[patent_app_number] => 16/502498
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 14527
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 195
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502498
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/502498 | Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination | Jul 2, 2019 | Issued |
Array
(
[id] => 20227987
[patent_doc_number] => 12416636
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-16
[patent_title] => Personalized treatment of pancreatic cancer
[patent_app_type] => utility
[patent_app_number] => 17/059727
[patent_app_country] => US
[patent_app_date] => 2019-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 32
[patent_no_of_words] => 9143
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 161
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17059727
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/059727 | Personalized treatment of pancreatic cancer | May 30, 2019 | Issued |
Array
(
[id] => 15145083
[patent_doc_number] => 20190351019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => STEROID ADMINISTRATION AND IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 16/421763
[patent_app_country] => US
[patent_app_date] => 2019-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40284
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421763
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/421763 | STEROID ADMINISTRATION AND IMMUNOTHERAPY | May 23, 2019 | Abandoned |
Array
(
[id] => 16794102
[patent_doc_number] => 20210123919
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 17/052133
[patent_app_country] => US
[patent_app_date] => 2019-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17148
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052133
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/052133 | BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST | May 12, 2019 | Abandoned |
Array
(
[id] => 15180883
[patent_doc_number] => 20190361033
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-28
[patent_title] => DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/407699
[patent_app_country] => US
[patent_app_date] => 2019-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14361
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16407699
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/407699 | DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES | May 8, 2019 | Abandoned |
Array
(
[id] => 15432385
[patent_doc_number] => 20200030375
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => THERAPY AND METHODS OF INTRODUCING IMMATURE DENDRITIC CELLS AND/OR CYTOXIC T LYMPHOCYTE AND ANTI PD-1 / PD-L1 ANTIBODY FOR TREATMENT OF TUMORS
[patent_app_type] => utility
[patent_app_number] => 16/404091
[patent_app_country] => US
[patent_app_date] => 2019-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9199
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16404091
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/404091 | THERAPY AND METHODS OF INTRODUCING IMMATURE DENDRITIC CELLS AND/OR CYTOXIC T LYMPHOCYTE AND ANTI PD-1 / PD-L1 ANTIBODY FOR TREATMENT OF TUMORS | May 5, 2019 | Abandoned |
Array
(
[id] => 14836271
[patent_doc_number] => 20190276536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => HUMANIZED ANTIBODIES WITH INCREASED STABILITY
[patent_app_type] => utility
[patent_app_number] => 16/398472
[patent_app_country] => US
[patent_app_date] => 2019-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398472
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/398472 | Humanized antibodies with increased stability | Apr 29, 2019 | Issued |